Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTRN | P46939 | 8/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29702319 | 1.00 | UTRN (0.48) | UTRNCYP1A2AHRHDAC6MAPT | |
| SCHEMBL9558560 | 0.89 | PPARG (0.49) | HDAC6MAPTALDH1A1KDM4ENPC1 | |
| SCHEMBL377496 | 0.84 | FFAR1 (0.43) | MAPTALDH1A1SMN1; SMN2PPARGFFAR1 | |
| SCHEMBL9830775 | 0.81 | PPARG (0.43) | HDAC6MAPTALDH1A1KDM4EPPARG | |
| SCHEMBL30853454 | 0.80 | UTRN (0.46) | UTRNCYP1A2AHRHDAC6MAPT | |
| SCHEMBL13846702 | 0.80 | PPARG (0.59) | MAPTALDH1A1PPARGFFAR1NPSR1 | |
| SCHEMBL9833514 | 0.79 | MAOA (0.43) | MAPTESR1ALDH1A1KDM4EMEN1 | |
| SCHEMBL9830580 | 0.79 | MAOB (0.55) | CYP1A2HDAC6MAPTALDH1A1KDM4E | |
| SCHEMBL9831485 | 0.77 | PPARG (0.52) | MAPTALDH1A1PPARGFFAR1AKT1 | |
| SCHEMBL9435871 | 0.76 | PPARG (0.46) | MAPTALDH1A1PPARGFFAR1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 352 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931350-B2 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-08-04 | — | — | EP | claimed |
| EP-1942898-B2 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2014-05-14 | — | — | EP | claimed |
| EP-1931350-B1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-20 | — | — | EP | claimed |
| EP-1942898-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | claimed |
| US-20110212982-A1 | Administration of Dipeptidyl Peptidase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-01 | — | — | US | claimed |
| US-20110192748-A1 | Administration of Dipeptidyl Peptidase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-11 | — | — | US | claimed |
| EP-1942898-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-07-16 | — | — | EP | claimed |
| EP-1931350-A2 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2008-06-18 | — | — | EP | claimed |
| WO-2007033265-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETIS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | WO | claimed |
| WO-2007033266-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETIS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | WO | claimed |
| WO-2007033350-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | WO | claimed |
| US-20070060529-A1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | DEVELOPMENT PARTNERS, LLC | 2007-03-15 | — | — | US | claimed |
| US-20070060530-A1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-03-15 | — | — | US | claimed |
| WO-2006034435-A2 | METHODS AND COMPOSITIONS FOR TREATING GLUCOSE-ASSOCIATED CONDITIONS, METABOLIC SYNDROME, DYSLIPIDEMIAS AND OTHER CONDITIONS | POINT THERAPEUTICS, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| WO-2024055932-A1 | AZACYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | 亚宝药业集团股份有限公司 | 2024-03-21 | — | — | WO | disclosed |
| US-20240036046-A1 | CANCER EXAMINATION METHOD AND CANCER TREATMENT AGENT | IMAMITSUKAI MEDICAL CORPORATION (JP) | 2024-02-01 | — | — | US | disclosed |
| WO-2001052825-A2 | COMBINATIONS COMPRISING DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2001-07-26 | — | — | WO | disclosed |
| WO-2001047514-A1 | USE OF HYPOGLYCEMIC AGENT FOR TREATING IMPAIRED GLUCOSE METABOLISM | NOVARTIS AG (CH) | 2001-07-05 | — | — | WO | disclosed |
| WO-2001026639-A2 | PHARMACEUTICAL COMPOSITION OF ATEGLINIDE AND ANOTHER ANTIDIABETICAGENT | NOVARTIS AG (CH) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110192748-A1 | Administration of Dipeptidyl Peptidase Inhibitors | DPP4, DPP7, DPP3 | UTRN 698/4885CYP1A2 1546/4885AHR 2407/4885 |
| US-20070060530-A1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP7, DPP3 | UTRN 698/4885CYP1A2 1546/4885AHR 2407/4885 |
| US-20110212982-A1 | Administration of Dipeptidyl Peptidase Inhibitors | DPP4, DPP7, DPP3 | UTRN 781/4885CYP1A2 1509/4885AHR 2660/4885 |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | UTRN 2474/4885CYP1A2 3827/4885AHR 3509/4885 |
| US-20070060529-A1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | DPP7, DPP4, DPP3 | UTRN 697/4885CYP1A2 1370/4885AHR 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.